{
  "_metadata": {
    "version": "2.1",
    "ticker": "EWTX",
    "asset_name": "EDG-003",
    "extraction_date": "2026-02-11",
    "source_id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf"
  },
  "asset": {
    "name": "EDG-003",
    "company": "Edgewise Therapeutics",
    "ticker": "EWTX",
    "stage": "Preclinical",
    "modality": "Small molecule",
    "ownership": "Wholly-owned",
    "one_liner": "EDG-003 is a preclinical small molecule targeting an undisclosed target for cardiometabolic diseases, part of Edgewise's muscle-focused platform."
  },
  "target": {
    "name": "Undisclosed target",
    "full_name": "Undisclosed target",
    "class": "Unknown",
    "pathway": "Cardiometabolic pathway",
    "biology": {
      "simple_explanation": "EDG-003 targets an undisclosed pathway in cardiometabolic diseases. The specific target and mechanism have not been disclosed by Edgewise Therapeutics.",
      "pathway_detail": null,
      "downstream_effects": null
    },
    "why_good_target": {
      "clinical_validation": null,
      "genetic_validation": {
        "gain_of_function": null,
        "loss_of_function": null
      },
      "source": {
        "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
        "slide": 5,
        "verified": false
      }
    }
  },
  "mechanism": {
    "type": "Unknown",
    "how_it_works": "Mechanism of action not disclosed",
    "differentiation": "Differentiation not disclosed at this preclinical stage",
    "source": {
      "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
      "slide": 5,
      "verified": false
    }
  },
  "regulatory": {
    "designations": [],
    "planned_pathway": {
      "type": null,
      "surrogate_endpoint": null,
      "source": {
        "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
        "slide": null,
        "verified": false
      }
    }
  },
  "partnership": {
    "_note": "Wholly-owned; no partnership",
    "partner": null,
    "territory": null,
    "economics": null
  },
  "pharmacology": {
    "pk_parameters": {
      "half_life": {
        "value": null,
        "population": null,
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      },
      "cmax": {
        "value": null,
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      },
      "auc": {
        "value": null,
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      },
      "tmax": {
        "value": null,
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      },
      "bioavailability": {
        "value": null,
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      },
      "volume_of_distribution": {
        "value": null,
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      }
    },
    "dose_response": {
      "doses_tested": null,
      "dose_rationale": null,
      "exposure_response": null,
      "recommended_dose": {
        "dose": null,
        "rationale": null,
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      },
      "by_dose": null
    },
    "target_engagement": {
      "metric": null,
      "by_dose": null
    },
    "pk_summary": "No pharmacology data disclosed for preclinical asset"
  },
  "indications": {
    "lead": {
      "name": "Cardiometabolic diseases",
      "patient_population": "Patients with cardiometabolic conditions",
      "current_penetration": "Not disclosed",
      "rationale": "Part of Edgewise's muscle-focused platform addressing cardiometabolic conditions",
      "source": {
        "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
        "slide": 5,
        "verified": false
      }
    },
    "expansion": []
  },
  "clinical_data": {
    "trials": []
  },
  "differentiation_claims": [],
  "competitive_landscape": {
    "competitors": [],
    "_note": "No competitive information disclosed for preclinical cardiometabolic program"
  },
  "ip_landscape": {
    "composition_of_matter": {
      "patent_expiry": null,
      "source": {
        "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
        "slide": null,
        "verified": false
      }
    },
    "method_of_use": {
      "patent_expiry": null,
      "source": {
        "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
        "slide": null,
        "verified": false
      }
    },
    "regulatory_exclusivity": {
      "type": null,
      "expiry": null
    },
    "freedom_to_operate": null
  },
  "market_opportunity": {
    "tam": null,
    "patient_population": null,
    "unmet_need": "Cardiometabolic diseases represent significant unmet medical need",
    "pricing_benchmark": null,
    "peak_sales_estimate": null,
    "source": {
      "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
      "slide": 5,
      "verified": false
    }
  },
  "catalysts": [],
  "investment_analysis": {
    "probability_of_success": null,
    "key_risks": [
      "Early stage preclinical asset with significant development risk",
      "Undisclosed target and mechanism limit assessment"
    ],
    "bull_case": [
      {
        "thesis": "Edgewise has demonstrated expertise in muscle biology that could translate to cardiometabolic success",
        "evidence": "Company's proven muscle-focused platform with sevasemten and EDG-7500",
        "confidence": "low"
      }
    ],
    "bear_case": [
      {
        "thesis": "Very early stage asset with no disclosed data or clear development timeline",
        "evidence": "Preclinical stage with undisclosed target, mechanism, and timeline",
        "confidence": "high"
      }
    ],
    "key_debates": [
      {
        "question": "Will Edgewise advance EDG-003 or focus resources on more advanced programs?",
        "bull_view": "Company's muscle expertise could drive rapid development",
        "bear_view": "Limited disclosure suggests lower priority versus advanced assets",
        "what_resolves_it": "Future development timeline and data disclosure"
      }
    ]
  },
  "_extraction_quality": {
    "completeness_score": "low",
    "missing_critical_fields": [
      "target",
      "mechanism",
      "clinical_data",
      "pharmacology",
      "timeline",
      "competitive_positioning"
    ],
    "recommended_supplementary_sources": [
      "SEC filings with more detailed pipeline description",
      "Scientific publications on cardiometabolic targets",
      "Investor presentations with more EDG-003 detail"
    ]
  }
}